Key facts
- Calla Lily Clinical Care’s last known valuation is $14.4M (Jan 2025).
- It has raised $6.9M across 1 recorded rounds; the latest was Accelerator/Incubator in Mar 2025.
- Notable investors include Innovate UK, Springboard Enterprises, Conduit Connect, HH Global Partners, Science Center.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Calla Lily Clinical Care
Funding rounds
1 roundsAbout Calla Lily Clinical Care
Developer of women-specific drug-delivery systems designed to improve patient outcomes. The company specializes in patented vaginal drug delivery devices to broad range of therapeutics targeting fertility, gynecological cancers, and vaginal microbiome, it offers a drug-device combo product to prevent miscarriages and for In Vitro Fertilization luteal phase support and can also deliver live biotherapeutics to reduce recurrent Bacterial Vaginosis, cutting antibiotic usage, enabling patients to access a safer and patient-friendlier way of progesterone administration which reduces the spread of antimicrobial resistance.
- Industry
- Drug Delivery
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2021
- Employees
- 32
- Website
- callali.ly/
- Ownership
- Privately Held (backing)
Calla Lily Clinical Care doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Calla Lily Clinical Care shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Calla Lily Clinical Care in its N-PORT filings yet. We sweep new filings monthly.